Analyst Price Targets — VERA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 19, 2025 12:20 pm | — | Goldman Sachs | $95.00 | $47.69 | TheFly | Vera Therapeutics price target raised to $95 from $55 at Goldman Sachs |
| December 11, 2025 1:21 pm | Laura Chico | Wedbush | $33.00 | $45.42 | TheFly | Vera Therapeutics price target raised to $33 from $23 at Wedbush |
| December 8, 2025 1:34 pm | Gavin Clark-Gartner | Evercore ISI | $97.00 | $45.79 | TheFly | Vera Therapeutics price target raised to $97 from $75 at Evercore ISI |
| December 5, 2025 9:49 am | — | Pivotal Research | $73.00 | $42.61 | StreetInsider | Vera Therapeutics (VERA) PT Raised to $73 at TD Cowen |
| November 28, 2025 11:35 am | — | H.C. Wainwright | $90.00 | $33.33 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Vera Therapeutics (VERA) |
| June 3, 2025 2:03 pm | Greg Harrison | Scotiabank | $65.00 | $30.91 | TheFly | Vera Therapeutics price target raised to $65 from $55 at Scotiabank |
| March 21, 2024 6:01 am | Laura Chico | Wedbush | $34.00 | $42.87 | StreetInsider | Vera Therapeutics (VERA) PT Raised to $34 at Wedbush |
| January 26, 2024 6:47 am | Ryan Deschner | Raymond James | $37.00 | $30.18 | StreetInsider | Raymond James Upgrades Vera Therapeutics (VERA) to Strong Buy |
| December 18, 2023 1:59 pm | Ryan Deschner | Raymond James | $29.00 | $15.84 | Benzinga | Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst |
| January 4, 2023 10:29 am | — | Jefferies | $6.00 | $6.37 | Benzinga | Jefferies Downgrades Vera Therapeutics to Hold, Lowers Price Target to $6 |
Latest News for VERA
BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares of Class A common stock and restricted stock units (RSUs) underlying 131,925 shares of Class…
JPMorgan Chase and Co. cut its position in shares of Vera Therapeutics, Inc. (NASDAQ: VERA) by 73.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,365 shares of the company's stock after selling 228,182 shares during the period. JPMorgan
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.
BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 56,850 shares of Class A common stock and restricted stock units (RSUs) underlying 42,403 shares of Class A…
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VERA.
U.S. House Trading
No House trades found for VERA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.